BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines External Cost of Development Programs by Quarter
External Cost of Development Programs ($M) ($M)
BeOne Medicines External Cost of Development Programs: $194M in Q2 2026, up 6.3% from a year earlier.
Where the Q2 2026 figure comes from
“|| Cost of development programs | $ | 194,035 | $ | 182,567 | $ | 11,468 | 6.3 | %”
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K MD&A R&D Expense Summary Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up external Cost of Development Programs
- External R&D — BRUKINSA (zanubrutinib, BTKi) ($M)–
- External R&D — TEVIMBRA (tislelizumab, Anti-PD-1) ($M)–
- External R&D — BEQALZI / Sonrotoclax (BGB-11417, BCL2 Inhibitor) ($M)–
- External R&D — Tacabrutideg (BGB-16673, BTK CDAC) ($M)–
- External R&D — BGB-43395 (CDK4 Inhibitor) ($M)–
- External R&D — PARTRUVIX (pamiparib, PARP Inhibitor) ($M, FY17–FY23)–
- External R&D — Ociperlimab (BGB-A1217, Anti-TIGIT) ($M, FY20–FY23)–
- External R&D — BGB-A445 (Anti-OX40 Agonist) ($M, FY20–FY23)–
- External R&D — Other Internal Clinical & Preclinical Projects ($M)–
- External R&D — R&D Collaboration Projects ($M)–
Cite this data
StockData. (2026). BeOne Medicines External Cost of Development Programs ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-ext-dev-programs
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.